Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to $3.3 million.

  • Tg Therapeutics' Other Non Operating Income rose 2246.81% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 9886.14%. This contributed to the annual value of $7.7 million for FY2024, which is 5251.78% up from last year.
  • As of Q3 2025, Tg Therapeutics' Other Non Operating Income stood at $3.3 million, which was up 2246.81% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Other Non Operating Income registered a high of $3.6 million during Q1 2025, and its lowest value of $604000.0 during Q1 2023.
  • For the 4-year period, Tg Therapeutics' Other Non Operating Income averaged around $1.9 million, with its median value being $1.9 million (2022).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first crashed by 5388.6% in 2023, then skyrocketed by 30943.18% in 2025.
  • Quarter analysis of 4 years shows Tg Therapeutics' Other Non Operating Income stood at $1.9 million in 2022, then tumbled by 53.89% to $890000.0 in 2023, then soared by 188.2% to $2.6 million in 2024, then rose by 27.29% to $3.3 million in 2025.
  • Its Other Non Operating Income stands at $3.3 million for Q3 2025, versus $2.8 million for Q2 2025 and $3.6 million for Q1 2025.